Hardev Pandha

Hardev Pandha

Professor of Medical Oncology



Hardev Pandha is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London. He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006.

His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.

Research interests

Tumour Immunology

Urological Cancer

Gene Therapy

For further information, please visit our Cancer Research theme page

My publications



Donnelly O, Harrington K, Melcher A, Pandha H Live viruses to treat cancer. J R Soc Med. 2013 Aug;106(8):310-4.


Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, Domchek S, Douglas F, Eccles D, Evans DG, Harris M, Kirk J, Lam J, Lindeman G, Mitchell G, Pachter N, Selkirk C, Tucker K, Zgajnar J, Eeles R, Pandha H. Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep. 2013;3:2059.


Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R. Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Mol Ther. 2013 Aug;21(8):1507-16

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling. Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ. Oncogene. 2013 Apr 29.

Prostate cancer vaccines. Michael A, Relph K, Annels N, Pandha H. . Expert Rev Vaccines. 2013 Mar;12(3):253-62.

Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker.

Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, Knowles MA, Pandha H.

Eur J Cancer. 2013 Feb 21. doi:pii: S0959-8049(13)00081-6. 10.1016/j.ejca.2013.01.019. [Epub ahead of print]


The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway.

Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M, Tripodo C, Colombo MP, Morgan R, Carè A.

Int J Cancer. 2013 Feb 7. doi: 10.1002/ijc.28097. [Epub ahead of print]


Engrailed homeobox transcription factors as potential markers and targets in cancer.

McGrath SE, Michael A, Pandha H, Morgan R.

FEBS Lett. 2013 Feb 7. doi:pii: S0014-5793(13)00099-9. 10.1016/j.febslet.2013.01.054. [Epub ahead of print]


Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression.

Mackenzie Ross AD, Cook MG, Chong H, Hossain M, Pandha HS, Bennett DC.

Pigment Cell Melanoma Res. 2013 Mar;26(2):226-35. doi: 10.1111/pcmr.12060. Epub 2013 Jan 14.


The role of HOX genes in normal hematopoiesis and acute leukemia.

Alharbi RA, Pettengell R, Pandha HS, Morgan R.

Leukemia. 2012 Dec 5. doi: 10.1038/leu.2012.356. [Epub ahead of print]


Basaloid carcinoma of the prostate: A literature review with case report.

Tuan J, Pandha H, Corbishley C, Khoo V.

Indian J Urol. 2012 Jul;28(3):322-4. doi: 10.4103/0970-1591.102714.


Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.


Targeting the HOX/PBX dimer in breast cancer.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS.

Breast Cancer Res Treat. 2012 Nov;136(2):389-98. doi: 10.1007/s10549-012-2259-2. Epub 2012 Sep 30.


The hitchhiker's guide to virotherapy.

Donnelly O, Vile R, Pandha H, Harrington K, Melcher A.

Oncotarget. 2012 Aug;3(8):735-6. No abstract available.


Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.


Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2012 Aug 16. doi: 10.1038/gt.2012.68. [Epub ahead of print]


Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA.

Sci Transl Med. 2012 Jun 13;4(138):138ra77. doi: 10.1126/scitranslmed.3003578.


Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R.

BJU Int. 2012 Sep;110(6 Pt B):E287-92. doi: 10.1111/j.1464-410X.2012.11208.x. Epub 2012 May 15.


Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Nat Biotechnol. 2012 Mar 18;30(4):337-43. doi: 10.1038/nbt.2157.


Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.


Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS.

Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12.


Measles virus causes immunogenic cell death in human melanoma.

Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA.

Gene Ther. 2013 Jan;20(1):7-15. doi: 10.1038/gt.2011.205. Epub 2011 Dec 15.


Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?

Middleton GW, Annels NE, Pandha HS.

Cancer Immunol Immunother. 2012 Jan;61(1):1-7. doi: 10.1007/s00262-011-1151-y. Epub 2011 Nov 16. Review.


Antiangiogenic effects of zoledronate on cancer neovasculature.

Metcalf S, Pandha HS, Morgan R.

Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113. Review







Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med. 2011 Jun 19.

Heinemann L, Simpson GR, Boxall A, Kottke T, Relph K, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011 Jun 6;11(1):221.


Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011 Jun 5.

4. Hamdan S, Verbeke CS, Fox N, Booth J, Bottley G, Pandha HS, Blair GE The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells. Cancer Gene Ther. 2011 May 13.


Gray S, Pandha HS, Michael A, Middleton G, Morgan R. HOX Genes in Pancreatic Development and Cancer. Journal of the pancreas. 2011 May 6;12(3):216-9.


Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, et al. Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization. Clin Cancer Res. 2011 Mar 9 6.747


Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2011 Mar 1;17(5):1090-8. 6.747


Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer. 2011;10:20. 4.160


Baynes S WB, Ismail M, Khadra A, Davies J, . Cryochock following laparoscopic-assisted renal cryotherapy for renal cell carcinoma: a case report and review of literatures. Current Urology. 2011;5.


Ismail M SA, Davies aJ. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. British Journal Urology International. 2011;107:1009-10. 2.865




Anesti AM, Simpson GR, Price T, Pandha HS, Coffin RS. Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer. 2010;10:486. 2.736


Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. 6.747


Daniels TR, Neacato, II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 2010 Sep;24(9):1555-65. 8.296


Dash P, Barnett PV, Denyer MS, Jackson T, Stirling CM, Hawes PC, et al. Foot-and-mouth disease virus replicates only transiently in well-differentiated porcine nasal epithelial cells. J Virol. 2010 Sep;84(18):9149-60. 5.150


Faaij CM, Annels NE, Ruigrok G, van der Burg M, Ball LM, Bredius RG, et al. Decrease of skin infiltrating and circulating CCR10+ T cells coincides with clinical improvement after topical tacrolimus in Omenn syndrome. J Invest Dermatol. 2010 Jan;130(1):308-11. 5.543


Faaij CM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, et al. Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer. 2010 Aug;55(2):344-8. 2.134


Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010 Jun 1;16(11):3067-77. 6.747


Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. 6.489


Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, et al. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther. 2010 Dec;18(12):2085-93. 6.239


Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets. 2010 Mar 1;10(2):242-67. 5.129


Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, et al. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther. 2010 Sep;18(9):1599-605. 6.239


Ismail M, Morgan R, Harrington K, Davies J, Pandha H. Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model. Cryobiology. 2010 Dec;61(3):268-74. 1.718


James HE, Ebert K, McGonigle R, Reid SM, Boonham N, Tomlinson JA, et al. Detection of African swine fever virus by loop-mediated isothermal amplification. J Virol Methods. 2010 Mar;164(1-2):68-74. 2.133


John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 2010;11:14. 2.724


Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest. 2010 May 3;120(5):1551-60. 15.387


Michael A, John J, Meyer B, Pandha H. Activation and genetic modification of human monocyte-derived dendritic cells using attenuated Salmonella typhimurium. ScientificWorldJournal. 2010;10:393-401. 2


Michael A, Relph K, Pandha H. Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. Int J Cancer. 2010 Sep 1;127(6):1251-8. 4.722


Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010;10:89. 2.736


Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, et al. Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Ther. 2010 Aug;17(8):949-60. 4.745


Price DL LS, Han Z, Simpson G, Coffin RS, Wong J, Li S, Fong Y, Wong RJ, . Oncolysis using Herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head an neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136(2):151-8. 1.918


Wong J KK, Mittra A, Gonzalez SJ, Song KY, Simpson G, Coffin R, Fong Y. A third generation herpesvisus is effective against gastroesophageal cancer. J Surg Res. 2010;163(2):214-20. 2.176




Agrawal VK, Copeland KM, Barbachano Y, Rahim A, Seth R, White CL, et al. Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene Ther. 2009 Jan;16(1):78-92. 4.745


da Costa CE, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009 Mar;48(3):239-49. 3.858


Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer. 2009 Sep 15;125(6):1372-9. 4.722


Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009 May;16(5):689-99. 4.745


Ismail M, Bokaee S, Morgan R, Davies J, Harrington KJ, Pandha H. Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy. Br J Cancer. 2009 Jun 16;100(12):1889-95. 4.346


Ismail M, Morgan R, Harrington K, Davies J, Pandha H. Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model. Cryobiology. 2009 Oct;59(2):207-13. 1.718


Pandha H, D'Ambrosio C, Heenan S, Hyde N, Di Palma S, Nutting C, et al. Indium-labelled autologous dendritic cells migrate to local lymph nodes after intratumoural injection in head and neck cancer patients. Clin Oncol (R Coll Radiol). 2009 May;21(4):363-4. 2.846


Pandha H, Melcher A, Harrington K, Vile R. Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther. 2009 Jun;17(6):934-5. 6.239


Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009 Oct 1;15(19):6158-66. 6.747


Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009 Feb 10;100(3):470-5. 4.346


Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009 Oct;20(10):1119-32. 4.202


Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol. 2009 Oct 1;183(7):4312-21. 5.646


Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res. 2009 Jul 1;15(13):4374-81. 6.747


Prestwich RJ, Scott KJ, Brown J, Harnden P, Whelan P, Cartledge J, et al. The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int. 2009 Mar;103(6):740-6. 2.865


Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. 3.791




Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, et al. Renal oncocytoma: a case report and short review of the literature. Eur J Intern Med. 2008 Nov;19(7):e67-9. 1.385


Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. 2.846


Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med. 2008 Jan;14(1):81-7. 27.136


Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol. 2008 May 1;180(9):6018-26. 5.646


Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 2008 Sep;15(18):1257-70. 4.745


Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther. 2008 Aug;10(4):362-70. 3.452


Havranek EG, Labarthe MC, Ward S, Anderson CJ, Whelan MA, Pandha H. A novel murine model of allogeneic vaccination against renal cancer. BJU Int. 2008 May;101(9):1165-9. 2.865


Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, et al. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res. 2008 Dec 1;68(23):9771-8. 7.543


Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, et al. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res. 2008 Aug 1;14(15):4915-24.


Horvath A. And Mostafid H. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. BJU International. 2008;103(6):726-9. 2.865


Ismail M, Pandha, H and Davies, J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: current status and future prospectives. Future medicine. 2008;5(1):37-45.


Li Y, Stirling CM, Denyer MS, Hamblin P, Hutchings G, Takamatsu HH, et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Vaccine. 2008 May 19;26(21):2647-56. 3.616


Lowenstein L, Kenton K, Dooley Y, E RM, Brubaker L. Women who experience detrusor overactive at lower bladder volumes report greater bother. Neurourol Urodyn. 2008;27(1):45-7. 4.984


Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 2009;12(1):13-6. 2.096


Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res. 2008 Feb 1;14(3):912-23. 6.747


Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008 Nov 1;14(21):7127-37. 6.747


White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, et al. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Ther. 2008 Mar;15(6):424-33. 4.745


White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther. 2008 Jun;15(12):911-20. 4.745


Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs. 2008 Dec;17(12):1925-35. 4.218


Morgan R and Whiting K. Differential expression of HOX genes upon activation of leukocytre sub-populations. Int J Haematol. 2008;87(256-249). 1.168


Papaetis GS, Karapanagiotou LM, Pandha H, Syrigos KN. Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des. 2008;14(22):2229-51. 4.414


Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res. 2008 Nov 15;14(22):7358-66. 6.747


Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. 2.493


Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008 Jan 1;14(1):259-69. 6.747


Shears L, Plowright L, Harrington K, Pandha HS, Morgan R. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol. 2008 Nov;180(5):2196-201. 4.016




da Costa CE, Egeler RM, Hoogeboom M, Szuhai K, Forsyth RG, Niesters M, et al. Differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease. J Pathol. 2007 Jun;212(2):188-97. 6.466


Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med. 2007 Feb;9(2):99-106. 2.968


Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007 Oct;100(4):760-4. 2.865


Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007 Jun;177(6):2136-40; discussion 40. 4.016